2016: Great Lakes Neuroscience and NIH exclusive license on MS/ALS patent

The following is the KEI comment to the NIH proposed exclusive license to Great Lakes Neuroscience for a patent on Multiple Sclerosis, Amyotrophic Lateral Sclerosis and certain other CNS Disorders. (PDF version here). KEI asks the NIH for certain information about the proposed license, and also asks the NIH to include provisions in the license that protect consumers in both the United States and developing countries.If the geographic area includes worldwide rights, KEI asks that “the products should be made available at affordable prices in developing countries,” andKEI notes GSK has recently announced it has begun negotiations with the MPP to license the patents for its oncology products, and certainly the NIH can be at least as sensitive to the health needs of patients living in developing countries as is…


Link to Full Article: 2016: Great Lakes Neuroscience and NIH exclusive license on MS/ALS patent